ISPOR - Use of PD-L1 Biomarker in Second Line Therapy for Non-Small Cell Lung Cancer- Budget Impact Analysis from a Private Payer Perspective In Brazil

Full Text

Use of PD-L1 Biomarker in Second Line Therapy for Non-Small Cell Lung Cancer- Budget Impact Analysis from a Private Payer Perspective In Brazil

Abstract

Authors

L Chabrol Haas MB Coutinho RB Peixoto AS Ranieri FB Serra

Back to Volume 21, Supplemental S1

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now